Insomnia in patients with depression: Some pathophysiological and treatment considerations

CNS Drugs

Volumn 23, Issue 4, 2009, Pages 309-329

  Jindal, Ripu D ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; HYPNOTIC AGENT; MELATONIN; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

BEHAVIOR THERAPY; BRAIN METABOLISM; CLINICAL PRACTICE; COGNITIVE THERAPY; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DRIVING ABILITY; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; ELECTROOCULOGRAM; GLUCOSE BRAIN LEVEL; HEADACHE; HUMAN; HYPERSOMNIA; INSOMNIA; MENTAL DISEASE; MONOTHERAPY; NARCOLEPSY; NONREM SLEEP; PATHOPHYSIOLOGY; POLYPHARMACY; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REBOUND; REBOUND INSOMNIA; RELAXATION TRAINING; REM SLEEP; REVIEW; RISK BENEFIT ANALYSIS; SHIFT WORKER; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; TASTE DISCRIMINATION; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; HUMANS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 66249123937     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923040-00004     Document Type: Review

References (185)

1. Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord 1992; 26 (2): 117-25
2. Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry 2002; 159 (9): 1470-9
3. Parker G, Malhi G, Hadzi-Pavlovic D, et al. Sleeping in? The impact of age and depressive sub-type on hypersomnia. J Affect Disord 2006; 90 (1): 73-6
4. Paudel ML, Taylor BC, Diem SJ, et al. Association between depressive symptoms and sleep disturbances in community-dwelling older men. Osteoporotic Fractures in Men Study Group. J Am Geriatr Soc 2008 Jul; 56 (7): 1228-35
5. Buysse DJ, Tu XM, Cherry CR, et al. Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biol Psychiatry 1999; 45 (2): 205-13
6. Thase ME, Simons AD, Reynolds III CF. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch Gen Psychiatry 1996; 53 (2): 99-108
7. Dew MA, Reynolds III CF, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54 (11): 1016-24
8. Reynolds III CF, Frank E, Houck PR, et al. Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Am J Psychiatry 1997; 154 (7): 958-62
9. Cho HJ, Lavretsky H, Olmstead R, et al. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry 2008 Dec; 165 (12): 1543-50
10. Dombrovski AY, Cyranowski JM, Mulsant BH, et al. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy? Depress Anxiety 2008; 25 (12): 1060-6
11. Agargun MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry 1997; 58 (6): 249-51
12. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990; 147 (9): 1189-94
13. Goldstein TR, Bridge JA, Brent DA. Sleep disturbance preceding completed suicide in adolescents. J Consult Clin Psychol 2008 Feb; 76 (1): 84-91
14. Buysse DJ, Angst J, Gamma A, et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008 Apr 1; 31 (4): 473-80
15. Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep 2008 Oct 1; 31 (10): 1351-6
16. Pigeon WR, Hegel M, Unützer J, et al. Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep 2008 Apr 1; 31 (4): 481-8
17. Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev 2004; 8 (1): 19-30
18. Thase ME, Carpenter L, Kupfer DJ, et al. Clinical significance of reversed vegetative subtypes of recurrent major depression. Psychopharmacol Bull 1991; 27 (1): 17-22
19. Matza LS, Revicki DA, Davidson JR, et al. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 2003; 60 (8): 817-26
20. Thase ME, Himmelhoch JM, Mallinger AG, et al. Sleep EEG and DST findings in anergic bipolar depression. Am J Psychiatry 1989; 146 (3): 329-33
21. Thase ME, Kupfer DJ, Ulrich RF. Electroencephalographic sleep in psychotic depression: a valid subtype? Arch Gen Psychiatry 1986; 43 (9): 886-93
22. Feinberg M, Carroll BJ. Biological 'markers' for endogenous depression: effect of age, severity of illness, weight loss, and polarity. Arch Gen Psychiatry 1984; 41 (11): 1080-5
23. Frank E, Kupfer DJ, Hamer T, et al. Maintenance treatment and psychobiologic correlates of endogenous subtypes. J Affect Disord 1992; 25 (3): 181-9
24. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60 (4): 221-5
25. Manber R, Rush AJ, Thase ME, et al. The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep 2003; 26 (2): 130-6
26. Carney CE, Segal ZV, Edinger JD, et al. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry 2007; 68 (2): 254-60
27. Carskadon MA, Rechtsschaffen A. Monitoring and staging human sleep. In: Kryger MH, Roth T, Demen WC, editors. Principles and practice of sleep medicine. London: W.B. Saunders, 1994
28. Coburn KL, Lauterbach EC, Boutros NN, et al. The value of quantitative electroencephalography in clinical psychiatry: a report by the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2006; 18 (4): 460-500
29. Maquet P. Positron emission tomography studies of sleep and sleep disorders. J Neurol 1997; 244 (4 Suppl. 1): S23-8
30. Tasali E, Leproult R, Ehrmann DA, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A 2008 Jan 22; 105 (3): 1044-9
31. Horne J. Human slow wave sleep: a review and appraisal of recent findings, with implications for sleep functions, and psychiatric illness. Experientia 1992; 48 (10): 941-54
32. Kupfer DJ, Thase ME. The use of the sleep laboratory in the diagnosis of affective disorders. Psychiatr Clin North Am 1983; 6 (1): 3-25
33. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders. Arch Gen Psychiatry 1992; 49: 661-8
34. Jindal RD, Thase ME, Fasiczka AL, et al. Electro encephalographic sleep profiles in single-episode and recurrent unipolar forms of major depression: II. Comparison during remission. Biol Psychiatry 2002; 51 (3): 230-6
35. Armitage R. Microarchitectural findings in sleep EEG in depression: diagnostic implications. Biol Psychiatry 1995; 37 (2): 72-84
36. Jindal RD, Friedman ES, Berman SR, et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 2003; 23 (6): 540-8
37. Terzano MG, Parrino L, Sherieri A, et al. Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Med 2001; 2 (6): 537-53
38. Lopes MC, Quera-Salva MA, Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (agomelatine). Sleep Med 2007; 9 (1): 33-41
39. Farina B, Della Marca G, Grochocinski VJ, et al. Microstructure of sleep in depressed patients according to the cyclic alternating pattern. J Affect Disord 2003; 77 (3): 227-35
40. Nofzinger EA, Buysse DJ, Miewald JM, et al. Human regional cerebral glucose metabolism during non-rapid eye movement sleep in relation to waking. Brain 2002; 125 (Pt5): 1105-15
41. Braun AR, Balkin TJ, Wesenten NJ, et al. Regional cerebral blood flow throughout the sleep-wake cycle: an H2(15)O PET study. Brain 1997; 120 (Pt 7): 1173-97
42. Maquet P, Degueldre C, Delfiore G, et al. Functional neuroanatomy of human slow wave sleep. J Neurosci 1997; 17 (8): 2807-12
43. Nofzinger EA, Buysse DJ, Germain A, et al. Alterations in regional cerebral glucose metabolism across waking and non-rapid eye movement sleep in depression. Arch Gen Psychiatry 2005; 62 (4): 387-96
44. Nofzinger EA, Buysse DJ, Germain A, et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004; 161 (11): 2126-8
45. Thomas M, Sing H, Belenky G, et al. Neural basis of alertness and cognitive performance impairments during sleepiness: I. Effects of 24 h of sleep deprivation on waking human regional brain activity. J Sleep Res 2000; 9 (4): 335-52
46. Critchley HD, Corfield DR, Chandler MP, et al. Cerebral correlates of autonomic cardiovascular arousal: a functional neuroimaging investigation in humans. J Physiol 2000; 523 (Pt 1): 259-70
47. Steriade M. The corticothalamic system in sleep. Front Biosci 2003; 8: 878-99
48. Jones BE. The neural bais of consciousness across the sleep-waking cycle. Adv Neurol 1998; 77: 75-94
49. McCarley RW, Massaquoi SG. A limit cycle mathematical model of the REM sleep oscillator system. Am J Physiol 1986; 251 (6 Pt 2): 1011-29
50. Stickgold R, Hobson JA, Fosse R, et al. Sleep, learning, and dreams: off-line memory reprocessing. Science 2001; 294 (5544): 1052-7
51. Lauer CJ, Riemann D, Wiegand M, et al. From early to late adulthood: changes in EEG sleep of depressed patients and healthy volunteers. Biol Psychiatry 1991; 29 (10): 979-93
52. Armitage R, Hoffmann R, Trivedi M, et al. Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. Psychiatry Res 2000; 95 (3): 201-13
53. Armitage R, Hoffmann R, Emslie G, et al. Sleep microarchitecture in childhood and adolescent depression: temporal coherence. Clin EEG Neurosci 2006; 37 (1): 1-9
54. Ware JC, Brown FW, Moorad Jr PJ, et al. Effects on sleep: a double-blind study comparing trimipramine to imipra-mine in depressed insomniac patients. Sleep 1989; 12 (6): 537-49
55. Shipley JE, Kupfer DJ, Griffin SJ, et al. Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients. Psychopharmacology (Berl) 1985; 85 (1): 14-22
56. Nofzinger EA, Reynolds III CF, Thase ME, et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995; 152 (2): 274-6
57. Winkelman JW, James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004; 27 (2): 317-21
58. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156 (5): 675-82
59. Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000; 126: 413-31
60. Germain A, Nofzinger EA, Meltzer CC, et al. Diurnal variation in regional brain glucose metabolism in depression. Biol Psychiatry 2007; 62 (5): 438-45
61. Nofzinger EA, Buysse DJ, Germain A, et al. Increased activation of anterior paralimbic and executive cortex from waking to rapid eye movement sleep in depression. Arch Gen Psychiatry 2004; 61 (7): 695-702
62. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005; 58 (6): 510-4
63. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58 (8): 348-50
64. Marshall NS, Yee BJ, Desai AV, et al. Two randomized placebo-controlled trials to evaluate the efficacy and tol-erability of mirtazapine for the treatment of obstructive sleep apnea. Sleep 2008; 31 (6): 824-31
65. Carley DW, Olopade C, Ruigt GS, et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 2007; 30 (1): 35-41
66. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002; 180: 528-35
67. van Bemmel AL, van den Hoofdakker RH, Beersma DG, et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalo-pram. Psychopharmacology (Berl) 1993; 113 (2): 225-30
68. Knab B, Engel RR. Perception of waking and sleeping: possible implications for the evaluation of insomnia. Sleep 1988; 11 (3): 265-72
69. Armitage R, Trivedi M, Hoffmann R, et al. Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depress Anxiety 1997; 5 (2): 97-102
70. Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients. Hum Psy-chopharmacol 2005; 20 (5): 349-54
71. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in in-patients with major depression. Psychopharmacol Bull 1996; 32 (4): 637-46
72. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68(11): 1723-32
73. Shelton RC, Prakash A, Mallinckrodt CH, et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract 2007; 61 (8): 1337-48
74. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007 Jun; 23 (6): 1303-18
75. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24 (4): 389-99
76. Kluge M, Schussler P, Steiger A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsycho-pharmacol 2007;17 (8): 527-31
77. Chalon S, Pereira A, Lainey E, et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005; 177 (4): 357-65
78. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17 (5): 239-47
79. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10 (5): 661-73
80. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16 (2): 93-100
81. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22 (5): 283-91
82. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10 (5): 691-6
83. Kupfer DJ, Frank E, McEachran AB, et al. Delta sleep ratio: a biological correlate of early recurrence in unipolar affective disorder. Arch Gen Psychiatry 1990; 47 (12): 1100-5
84. Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005; 63 (3): 298-304
85. Banasr M, Soumier A, Hery M, et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006; 59 (11): 1087-96
86. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19 (5): 271-80
87. Ying SW, Rusak B, Mocaer E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur J Pharmacol 1998; 342 (1): 29-37
88. Ott GE, Rao U, Lin KM, et al. Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response. Int J Neuropsychopharmacol 2004; 7 (3): 275-81
89. Kavoussi RJ, Segraves RT, Hughes AR, et al. Doubleblind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58 (12): 532-7
90. Weihs KL, Settle Jr EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61 (3): 196-202
91. Nofzinger EA, Fasiczka A, Berman S, et al. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61 (11): 858-62
92. Mouret J, Lemoine P, Minuit MP, et al. Effects of trazodone on the sleep of depressed subjects: a polygraphic study. Psychopharmacology (Berl) 1988; 95 Suppl.: S37-43
93. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990; 51 Suppl.: 13-7
94. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14 (3): 170-9
95. Beasley Jr CM, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52 (7): 294-9
96. Schwetz BA. From the Food and Drug Administration. JAMA 2002; 287 (9): 1103
97. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999; 14 (6): 329-37
98. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19 (2): 137-46
99. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21 (4): 425-31
100. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61 (9): 656-63
101. Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006; 26 (1): 75-8
102. Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003; 18 (4): 261-9
103. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalo-pram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005; 66 (4): 436-43
104. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25 (6): 677-9
105. Winokur A, Sateia MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000; 48 (1): 75-8
106. Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 2006; 51 (1): 27-34
107. Schmid DA, Wichniak A, hr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006; 31 (4): 832-44
108. Schittecatte M, Dumont F, Machowski R, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002; 46 (4): 197-201
109. Winokur A, DeMartinis III NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64 (10): 1224-9
110. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and nora-drenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62 (11): 1217-27
111. Dording CM, Mischoulon D, Petersen TJ, et al. The harmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002; 14 (3): 143-7
112. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151 (7): 1069-72
113. Kaynak H, Kaynak D, Gozukirmizi E, et al. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004; 5 (1): 15-20
114. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331 (7526): 1169-73
115. Cohn JB. Triazolam treatment of insomnia in depressed patients taking tricyclics. J Clin Psychiatry 1983; 44 (11): 401-6
116. Scharf MB, Hirschowitz J, Zemlan FP, et al. Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. J Clin Psychiatry 1986; 47 (12): 587-91
117. Nolen WA, Haffmans PM, Bouvy PF, et al. Hypnotics as concurrent medication in depression: a placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. J Affect Disord 1993; 28 (3): 179-88
118. Sussman N. Anxiolytic antidepressant augmentation. J Clin Psychiatry 1998; 59 Suppl. 5: 42-8; discussion 9-50
119. Smith WT, Londborg PD, Glaudin V, et al. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry 1998; 155 (10): 1339-45
120. Smith WT, Londborg PD, Glaudin V, et al. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord 2002; 70 (3): 251-9
121. Barbanoj MJ, Clos S, Romero S, et al. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. Neuropsychobiology 2005; 51 (3): 134-47
122. Kupfer DJ, Reynolds III CF. Management of insomnia. N Engl J Med 1997; 336 (5): 341-6
123. Perlis ML, McCall WV, Krystal AD, et al. Long-term, nonnightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004; 65(8): 1128-37
124. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55 (5): 192-9
125. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psy-chopharmacol 1999; 14 (5): 287-303
126. Voshaar RC, van Balkom AJ, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol 2004; 14 (4): 301-6
127. Ancoli-Israel S, Walsh JK, Mangano RM, et al. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999; 1 (4): 114-20
128. Hajak G, Muller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003; 98 (10): 1371-8
129. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60 (10): 668-76
130. Roth T, Hull SG, Lankford DA, et al. Intermezzo Study Group. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008 Sep 1; 31 (9): 1277-84
131. Parrino L, Smerieri A, Giglia F, et al. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin Neuropharmacol 2008 Jan-Feb;31 (1): 40-50
132. Blin O, Micallef J, Audebert C, et al. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol 2006; 26 (3): 284-9
133. Hindmarch I, Legangneux E, Stanley N, et al. A doubleblind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006; 62 (5): 538-45
134. Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006; 7 (5): 397-406
135. Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005; 181 (4): 790-8
136. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 1999; 145 (1): 39-51
137. Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, Zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med 2006; 2 (4): 417-23
138. Vermeeren A, Riedel WJ, van Boxtel MP, et al. Differentia residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002; 25 (2): 224-31
139. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000; 4 (6): 551-81
140. Hajak G. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. Drug Saf 1999; 21 (6): 457-69
141. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 139-45
142. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26 (7): 793-9
143. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6 (6): 487-95
144. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30 (8): 959-68
145. Fava M, McCall WV, Krystal A, et al. Eszopiclone coadministered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59 (11): 1052-60
146. Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007; 3 (1): 48-55
147. Deacon S, Staner L, Staner C, et al. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 2007; 30 (3): 281-7
148. Walsh JK, Mayleben D, Guico-Pabia C, et al. Efficacy of the selective extrasynaptic GABA(A) agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial. Sleep Med 2008 May; 9 (4): 393-402
149. Walsh JK, Moscovitch A, Burke J, et al. Efficacy and tolerability of indiplon in older adults with primary insomnia. Sleep Med 2007; 8 (7-8): 753-9
150. Lydiard RB, Lankford DA, Seiden DJ, et al. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. J Clin Sleep Med 2006; 2 (3): 309-15
151. Scharf MB, Black J, Hull S, et al. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep 2007; 30 (6): 743-52
152. Carter LP, Griffiths RR, Suess PE, et al. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects. J Pharmacol Exp Ther 2007; 322 (2): 749-59
153. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3 (5): 495-504
154. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7 (1): 17-24
155. Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007; 23 (5): 1005-14
156. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006; 63 (10): 1149-57
157. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007; 47 (4): 485-96
158. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psy-chopharmacol 2007; 22 (1): 1-9
159. Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008 Sep; 23 (5): 269-75
160. Endicott J, Paulsson B, Gustafsson U, et al. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 2008 Dec; 111 (2-3): 306-19
161. Jindal RD, Keshavan MS. Critical role of M3 muscarinic receptor in insulin secretion: implications for psycho-pharmacology. J Clin Psychopharmacol 2006; 26 (5): 449-50
162. Walsh JK, Perlis M, Rosenthal M, et al. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006; 2 (1): 35-41
163. Roth T, Wright Jr KP, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006; 29 (3): 335-41
164. Walsh JK, Randazzo AC, Stone K, et al. Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement? Sleep 2006; 29 (4): 433-43
165. Meolie AL, Rosen C, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med 2005; 1 (2): 173-87
166. Bliwise DL, Ansari FP. Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 2007; 30 (7): 881-4
167. Morin CM, Koetter U, Bastien C, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005; 28(11): 1465-71
168. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998; 155 (8): 1119-21
169. Taibi DM, Landis CA, Petry H, et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007; 11 (3): 209-30
170. Carman JS, Post RM, Buswell R, et al. Negative effects of melatonin on depression. Am J Psychiatry 1976; 133 (10): 1181-6
171. Leibenluft E, Feldman-Naim S, Turner EH, et al. Effects of xogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58 (9): 383-8
172. Edinger JD, Wohlgemuth WK, Radtke RA, et al. Does cognitive-behavioral insomnia therapy alter dysfunctional beliefs about sleep? Sleep 2001; 24 (5): 591-9
173. Morin CM, Blais F, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther 2002; 40 (7): 741-52
174. Edinger JD, Wohlgemuth WK, Radtke RA, et al. Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial. Sleep 2007; 30 (2): 203-12
175. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep 2003; 26 (2): 177-82
176. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999; 281 (11): 991-9
177. Jacobs GD, Pace-Schott EF, Stickgold R, et al. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004; 164 (17): 1888-96
178. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006; 29 (11): 1398-414
179. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep 2006; 29 (11): 1415-9
180. Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008 Apr 1; 31 (4): 489-95
181. Vaishnavi S, Gadde K, Alamy S, et al. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 2006; 26 (4): 373-8
182. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164 (8): 1242-9
183. Fava M, Thase ME, DeBattista C. A multicenter, placebocontrolled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66 (1): 85-93
184. Ninan PT, Hassman HA, Glass SJ, et al. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 2004; 65 (3): 414-20
185. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Dec; 27 (6): 614-9